Nine Square Therapeutics Revenue and Competitors

Location

$50M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Nine Square Therapeutics's estimated annual revenue is currently $2.4M per year.(i)
  • Nine Square Therapeutics's estimated revenue per employee is $77,500
  • Nine Square Therapeutics's total funding is $50M.

Employee Data

  • Nine Square Therapeutics has 31 Employees.(i)
  • Nine Square Therapeutics grew their employee count by -3% last year.

Nine Square Therapeutics's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP and Head BiologyReveal Email/Phone
3
VP Preclinical and Translational SciencesReveal Email/Phone
4
VP and Head ChemistryReveal Email/Phone
5
VP and Head BiologyReveal Email/Phone
6
Senior Director, Head Program ManagementReveal Email/Phone
7
Senior Director, Head Program Management and OperationsReveal Email/Phone
8
Project ManagerReveal Email/Phone
9
Associate ScientistReveal Email/Phone
10
Senior Research AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Nine Square Therapeutics?

Nine Square Therapeutics, founded by ATP and leading scientists at UCSF, is discovering and delivering novel small-molecule therapeutics for movement disorders including Parkinson’s, ALS, essential tremors, and dyskinesias. Nine Square applies leading capabilities in computational chemistry, biophysics, and computational biology and a machine-learning-enabled cell profiling platform for target identification, chemical optimization, and patient stratification.

keywords:N/A

$50M

Total Funding

31

Number of Employees

$2.4M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.5M313%N/A
#2
$3.6M31-6%N/A
#3
$3.6M3141%N/A
#4
$6.7M3148%N/A
#5
$5.6M3115%N/A